Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 345 across all filing types
Latest filing 2025-04-04 Declaration of Voting R…
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital" and explicitly references French regulations (AMF General Regulations, French Commercial Code) for reporting the total number of shares and voting rights as of a specific date (March 31, 2025). This type of periodic disclosure detailing the capital structure and voting power is a specific regulatory requirement. While it relates to share capital, it is not a general share issue announcement (SHA) or a transaction in own shares (POS). It is a mandatory disclosure of the current voting rights base. Among the provided codes, none perfectly match a 'Monthly Voting Rights Disclosure,' but it is a specific regulatory filing concerning share structure and rights. Given the options, this document is a specific regulatory disclosure. Since it is not a general announcement of a report (RPA) and is a specific regulatory data point, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory filing providing specific, periodic data required by the regulator (AMF). However, since it deals exclusively with the total number of shares and voting rights, it is a very specific type of capital/share information disclosure. If we strictly adhere to the definitions, RNS is the fallback. Let's re-evaluate if any other code fits better. It is not a dividend (DIV), not a major shareholding change (MRQ), and not a general capital change (SHA). It is a mandatory disclosure of the current share count for voting purposes. Given the highly specific nature of the other codes, RNS (Regulatory Filings) serves as the most appropriate catch-all for mandatory, non-standard disclosures like this one.
2025-04-04 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of March 31, 2025. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory requirement in France, often related to capital structure changes or mandatory periodic updates. While it relates to capital, it is not a financing announcement (CAP) or a general share issue (SHA), but rather a mandatory disclosure of the current share count. This specific disclosure about the total number of shares and voting rights aligns most closely with mandatory regulatory reporting concerning share structure, which often falls under general regulatory filings or specific capital structure notifications. Given the options, this is a mandatory periodic disclosure about the capital structure, which is distinct from a general share issue (SHA) or a transaction in own shares (POS). Since it is a specific, mandatory disclosure about the capital structure count, and not a general announcement of a dividend (DIV) or a major shareholding change (MRQ), it fits best under the general regulatory filing category (RNS) or potentially a specific capital structure update if one existed. However, since it is a formal, periodic report on the total number of shares and voting rights, it is a specific type of regulatory filing. In the context of the provided definitions, it is a formal regulatory disclosure that doesn't fit the other specific categories like ER, IR, or DIV. Therefore, RNS (Regulatory Filings / miscellaneous) is the most appropriate fallback for this specific, non-standard report type, although it is highly specific. Upon re-evaluation, this document is a direct report of the capital structure count, which is a fundamental piece of corporate information. It is not an announcement *about* a report (RPA). It is a direct report of share/voting rights count. This is a very specific type of regulatory filing. Given the options, RNS is the best fit as a mandatory regulatory disclosure that isn't covered by the other specific codes.
2025-04-04 French
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to a declaration of crossing shareholding thresholds, referencing French commercial code. It explicitly states that the entity Invus Public Equities, L.P. crossed the 5% threshold of capital and voting rights in MAAT PHARMA. This type of filing, reporting changes in significant share ownership levels, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and contains specific regulatory reporting content, not a general announcement of a report release.
2025-04-04 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated March 31, 2025, announcing that MaaT Pharma will present new preclinical data for MaaT034 at the American Association for Cancer Research (AACR) Annual Meeting. This type of announcement, detailing upcoming scientific presentations, clinical trial updates, and general company news released via a formal press release format, typically falls under a general Investor Relations or Regulatory Filing category. Since it is not a full financial report (10-K, IR), a specific earnings release (ER), a proxy statement (DEF 14A), or a formal regulatory filing like a DVA or DIRS, the most appropriate classification is a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the presentation itself. Given that it is an *announcement* about data being presented at a conference, and it doesn't fit the specific definitions for ER, IR, or IP (which is the presentation document), RNS serves as the best fit for a general, non-periodic corporate update/announcement that doesn't fit other specific categories. The document length (6590 chars) is substantial enough that it is not just a brief 'Report Publication Announcement' (RPA).
2025-03-31 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 95% confidence The document is a press release dated March 31, 2025, announcing that MaaT Pharma will present new preclinical data for its drug candidate MaaT034 at the American Association for Cancer Research (AACR) annual meeting. It details the findings, provides specifics about the AACR session, and includes background information on the company's pipeline (MaaT013/PICASSO trial) and general corporate information. This type of announcement, focusing on scientific data presentation and pipeline updates, is characteristic of an Investor Presentation (IP) or a general press release related to investor/scientific updates. Since it is a detailed announcement of scientific progress and future presentation, 'Investor Presentation' (IP) is the most fitting category, as it serves to inform investors about key scientific milestones, even though it is structured as a press release. It is not a formal regulatory filing like 10-K or a standalone Audit Report (AR). It is too detailed to be just an Earnings Release (ER) or a Report Publication Announcement (RPA).
2025-03-31 French
Inside Information / Information on annual revenues
Earnings Release Classification · 100% confidence The document explicitly states it reports the "2024 full-year annual results" and includes a "Condensed Income Statement" with audited results for the 12 months ending December 31, 2024, compared to 2023. This content structure, covering a full fiscal year's performance, aligns perfectly with the definition of an Annual Report. Although it also mentions a capital increase, the primary focus and detailed financial tables point to the annual reporting requirement. Since the document is extensive (over 33,000 characters) and contains the full results, it is classified as the report itself, not just an announcement of the report (RPA). The 10-K code is the standard SEC designation for an Annual Report, which is the closest equivalent for a comprehensive annual filing. FY 2024
2025-03-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.